JW Pharmaceutical announced on Feb. 26 that it has signed a joint research agreement with its subsidiary, C&C Pharmaceuticals Research Institute, for the development of innovative anti-cancer cell therapies.
According to the agreement, JW Pharmaceutical will develop a new CAR-NK cell therapy targeting solid tumors, in collaboration with the American biotech venture KURE.AI therapeutics and C&C Pharmaceuticals Research Institute.
JW Pharmaceutical secured the development rights in December last year, including sales royalties and technology fees, for the CAR-NK cell therapy, which was a key research project being co-developed with KURE.AI therapeutics by its research entity, JW CreaGene.
The company stated that this project is a joint research effort with KURE.AI therapeutics, which has an AI-based R&D platform in the field of cancer, aimed at launching in the global market by 2030, which began last year.
JW Pharmaceutical and the C&C Pharmaceuticals Research Institute plan to discover CAR-NK cell therapy candidates through joint research with KURE.AI therapeutics and to establish their own CAR-NK cell therapy R&D platform based on gene editing technology.
A representative from JW Pharmaceutical stated, “We will strengthen our cooperation with our key research subsidiary, C&C Pharmaceuticals Research Institute, and KURE.AI therapeutics in the United States, for the successful development of next-generation immunocell therapies for precision cancer treatment.”